Medical Condition News

RSS

AFQ056 drug improves symptoms in Fragile X patients: Study

The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise according to a new study published in the January issue of Science Translational Medicine.

9 Jan 2011

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

The U.S. Food and Drug Administration today approved Abstral transmucosal tablets to manage breakthrough pain for adults with cancer.

9 Jan 2011

Green tea may help in Alzheimer’s disease: Study

A new study finds that a cup of green tea may protect against Alzheimer’s disease and other forms of dementia. The researchers looked at the effects of a concentrated green tea extract that had been treated in the laboratory to mimic the effects of normal digestion.

9 Jan 2011

Simple Alzheimer’s disease test developed

The latest research has shown that a simple blood test could detect Alzheimer’s disease. Applying the same technology it could also detect hard-to-detect cancers and other diseases. The study reports appeared this Thursday in the journal Cell.

9 Jan 2011

Autism-vaccine link study – Complete fraud

There has been a controversy regarding the causative link of vaccines with autism. A report appeared in the British Medical Journal this Wednesday that stated that Dr. Andrew Wakefield, the lead author of a major study to imply such a link had falsified the medical histories of all 12 patients in his study and that he was “hoping to sue vaccine manufacturers and to create a vaccine scare.”

9 Jan 2011

Malaria drug makes cancer drug more effective

Scientists investigating the cancer-fighting properties of artesunate - a drug commonly used to treat malaria - have found early evidence that combining it with an existing cancer drug has the potential to make each drug more effective than when used alone. They also found that regular treatment breaks could improve success levels.

7 Jan 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity Pharmaceuticals, Inc. today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the year with a broad pipeline of four drug candidates in clinical development and a fifth expected to enter the clinic during the year. The company also enters 2011 with approximately $345 million in committed capital.

7 Jan 2011

PCPs and kidney specialists favor collaborative care for progressive chronic kidney disease

Most primary care physicians (PCPs) and kidney specialists favor collaborative care for a patient with progressive chronic kidney disease (CKD), but their preferences on how and when to collaborate differ, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). PCPs and kidney specialists need to partner more effectively to optimize care for patients with CKD.

7 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.

7 Jan 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

7 Jan 2011

Unexpected discovery holds promise for PTSD, other anxiety disorders

An unexpected discovery by UCLA life scientists holds promise for the future development of treatments for post-traumatic stress disorder and other anxiety disorders, and potentially for Alzheimer's disease and other memory-impairment diseases.

7 Jan 2011

Radiosurgery may bring improvement for patients with extremely severe -compulsive disorder

For patients with extremely severe -compulsive disorder (OCD), a procedure called radiosurgery may bring improvement when other treatments have failed, according to a study in the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

7 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011

Amorfix's AD diagnostic assay detects aggregated beta amyloid in spinal fluid

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced preliminary results indicating that their human Alzheimer's disease (AD) diagnostic assay can detect a signal from aggregated beta amyloid in the spinal fluid (CSF) from AD patients.

7 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

Medical Condition News

AFQ056 drug improves symptoms in Fragile X patients: Study

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

Green tea may help in Alzheimer’s disease: Study

Simple Alzheimer’s disease test developed

Autism-vaccine link study – Complete fraud

Malaria drug makes cancer drug more effective

Infinity provides guidance on anticipated pipeline and business goals for 2011

PCPs and kidney specialists favor collaborative care for progressive chronic kidney disease

Scientists identify type of cell at the origin of brain tumors

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Unexpected discovery holds promise for PTSD, other anxiety disorders

Radiosurgery may bring improvement for patients with extremely severe -compulsive disorder

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

MMRF awards $3 million under 2010 Biotech Investment Awards program

Amorfix's AD diagnostic assay detects aggregated beta amyloid in spinal fluid

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News